dystrophy (FSHD) is an incurable myopathy linked to 22 overexpression of DUX4. However, DUX4 is difficult to detect in FSHD myoblasts and 23 target gene expression is not a consistent FSHD muscle biopsy biomarker, displaying 24 efficacy only on pathologically inflamed samples. Immune gene misregulation occurs in 25 FSHD muscle biopsies with DUX4 targets enriched for inflammatory processes. However, 26 assessment of the FSHD immune cell transcriptome, and the evaluation of DUX4 and target 27 gene expression has not yet been performed. We show that FSHD lymphoblastoid cell lines 28 (LCLs) display robust DUX4 expression, and express early and late DUX4 targets. 29 Moreover, genes elevated on FSHD LCLs are elevated in FSHD muscle biopsies, correlating 30 with DUX4 target activation and histological inflammation. These genes are importantly 31 unaltered in FSHD myoblasts/myotubes, implying a non-muscle source in biopsies. Our 32 results indicate an immune cell source of DUX4 and target gene expression in FSHD muscle 33 biopsies. 34 35 36
Introduction
In summary, we postulate a role for DUX4 in immune cells in FSHD, and propose that 139 DUX4 target gene expression in FSHD muscle biopsies may not solely be driven by muscle 140 cells. DUX4 target gene expression in immune cells is likely to contribute to FSHD 141 pathology, being associated with early inflammatory changes, at a time when therapeutic 142 intervention may prevent irreversible change. 143
Results

145
FSHD LCLs display robust DUX4 expression 146 We identified 3 FSHD1 patients with gender and first degree relative matched controls, 147
which displayed large reported differences in DUX4 expression from the LCL cohort 148 described by Jones et al., 2017 33 . Namely: GSM16283 (FSHD1, 6RU, female, family 2) and 149 matched control GSM16281; GSM16414 (FSHD1, 6RU, female, family 11) and matched 150 control GSM16320; GSM16278 (FSHD1, 6RU, male, family 2) and matched control 151 GSM16412. RNA-seq was performed on each cell line in triplicate. 152 153 We also performed RNA-seq on 3 primary FSHD myoblast cell lines described previously 16 , 154 namely FSHD3 (FSHD1, 7RU, female), FSHD6 (FSHD1, 8RU, female) and FSHD9 155 (FSHD1, 7RU, male) alongside age and gender matched controls, in proliferation and after 3 156 days of differentiation into multinucleated myotubes, in singlet. This new RNA-Seq data was 157 considered with our previously published datasets of immortalised FSHD myoblasts and 158 myotubes in triplicate 23, 36 . This data describes 3 pathological FSHD cell lines (54-12, 54-A5 159 and 54-2, all FSHD1, 3RU, male) alongside 2 control lines (54-A10, 54-6, 11RU) from a 160 mosaic patient 37 as well as 2 further FSHD cell lines (16Abic, FSHD1, 7RU, female and 161 12Abic, FSHD1, 6RU, female) alongside sibling and gender matched controls (16Ubic and 162 12Ubic respectively). Thus, a total of 27 immortalised myoblasts and 27 immortalised 163 myotube RNA-seq samples. 164 165 DUX4 transcripts were detected by RNA-seq in all FSHD LCL samples (9/9, 100%), and in 166 2/3 replicates of control LCL GSM16320 (2/9, 22%), although at significantly lower levels 167 than its matched FSHD LCL GSM16414 (Fig. 1A) . After adjusting for gender and patient-168 control pair we found that DUX4 expression was significantly higher in FSHD LCLs 169 compared to controls (p=0.0099). myocytes, we found DUX4 expression in 27/5133 (0.5%) FSHD cells 32 . 178 179
FSHD LCLs and FSHD myotubes express high levels of early and late DUX4 target genes 180
while FSHD myoblasts express only late DUX4 target genes 181 We next considered expression of DUX4 target genes in our LCL, myoblast and myotube 182 transcriptomic analysis. We previously described 2 DUX4 target gene expression signatures 183 derived from transcriptomic assessments of human myoblasts over-expressing DUX4 for 184 different lengths of time 23 . A set of 212 DUX4 target genes were derived from data described 185
by Choi et al., 2016 38 against early and late DUX4 target gene expression scores in the single cell data, reveals a 277 peak of DUX4 expression in cells with low levels of DUX4 target genes, which decays as 278 DUX4 target genes increase (Fig S2) . This is consistent with a transient pulse of DUX4 279 expression occurring in differentiating FSHD myoblasts, which shuts down as DUX4 targets 280 are activated. 281 282
An FSHD lymphoblast signature is up-regulated in FSHD muscle biopsies and correlates 283 with DUX4 target gene expression 284
Given that FSHD LCLs express high levels of DUX4 and both early and late DUX4 target 285 genes, and that FSHD muscle biopsies are often characterised by inflammation in a manner 286 correlating with DUX4 target gene expression 24,26 , we next investigated whether an FSHD 287 LCL-derived gene expression signature can discriminate FSHD muscle biopsies from 288 controls. 289 290 We performed a differential expression analysis comparing FSHD LCLs to controls, 291
adjusting for gender and sibling matched pairs. We identified a large number of differentially 292 expressed genes and considered the 500 most significantly altered for further analysis. Of 293 these 237 were up-regulated in FSHD lymphocytes. As DUX4 is a known transcriptional 294 activator and genes suppressed under DUX4 expression do not add power to DUX4 target 295 based FSHD biomarkers 23 , we considered the mean expression of these 237 FSHD LCL up-296 regulated genes in a given sample as a putative FSHD biomarker, hereafter called the FSHD 297
Lymphoblast score ( Importantly, upregulation of the FSHD Lymphoblast score in FSHD muscle biopsies is 314 unlikely to be driven by muscle gene expression, since there was no significant difference in 315 expression of the FSHD Lymphoblast score on our RNA-seq data of FSHD and control 316 myoblasts (Wilcoxon p=0.76, Fig. 5A ) and myotubes (Wilcoxon p=0.81, Fig. 5B ). 317 318
We next computed expression of the 3 DUX4 target gene scores in the muscle biopsy data 319 sets. In line with our previous results, these formed weak but significant discriminators of 320 FSHD status, statistically equivalent to the FSHD Lymphoblast score, but inferior classifiers 321 of FSHD muscle biopsies to PAX7 target gene repression ( Fig. S3) . Evaluating associations 322 between the FSHD Lymphoblast score and the 3 DUX4 target gene expression scores across 323 the FSHD muscle biopsies revealed that the FSHD Lymphoblast score strongly associated 324 with the early DUX4 target genes (FSHD Lymphoblast score vs Choi et al., p<2.2x10 -16 , 325
Pearson's r=0.59, Fig. 5C ). A weaker but significant association was found between the 326 FSHD Lymphoblast score and the two late DUX4 target gene expression signatures (FSHD 327
Lymphoblast score vs Geng et al., p=1.5x10 -5 , Pearson's r=0.28, FSHD Lymphoblast score 328 vs Yao et al., p=0.01, Pearson's r=0.16 Fig. 5B ).
330
The FSHD Lymphoblast score is associated with histological inflammation in FSHD 331 muscle biopsies, independently of DUX4 target gene expression 332 FSHD LCL gene expression is elevated in FSHD muscle biopsies but not FSHD myoblasts or 333
myotubes, suggesting that the FSHD Lymphoblast score may be detecting immune cell 334 infiltrates in FSHD muscle biopsies. To investigate, we considered published RNA-seq data 335 of FSHD muscle biopsies alongside histological assessment of pathology score, inflammation 336 and active disease, together with MRI assessment of STIR and T1 positivity and fat 337 fraction 26 . Histological and MRI assessments are all metrics of active pathology in FSHD and 338 hence cross-correlate. We therefore built multivariate regression models evaluating which of 339 these variables was independently associated with the FSHD Lymphoblast score, or each of 340 the 3 DUX4 target gene expression signatures in turn. 341 342 Crucially, the FSHD Lymphoblast score associated only with histological inflammation 343 (p=0.016, Fig. 6 Although anti-inflammatory agents such as corticosteroids have been used in clinical trials 431
for FSHD without obvious benefit, the premise was that the inflammation was in response to 432 muscle pathology and effects on long term disease progression were not assessed 52 . 433
Moreover, expression of DUX4 and its target genes in lymphocytes may alter their function 434
to make them directly pathogenic. As such, if lymphocytes are a primary driver of FSHD, 435
rather than a secondary response, they may require more bespoke therapeutic interventions. 436 437
Given that the FSHD Lymphoblast score was derived from circulating blood borne 438 lymphocytes, this raises the possibility of blood cell-based biomarkers for FSHD, to measure 439 severity and progression. This minimally invasive method means that samples can be 440 regularly obtained, removing the need for repeated, often painful, muscle biopsies for disease 441 progression in routine clinical follow up and in FSHD clinical trials. Though blood-based 442 biomarkers for FSHD have been investigated previously, these have been based on panels of 443 serological tests, rather than assessment of blood borne cell transcriptomes and thus cannot be 444 expected to link to the FSHD causal DUX4 gene and its targets 53,54 . Importantly, our blood 445 cell-derived biomarker demonstrated discriminatory power and correlation with disease 446 activity when assessed on FSHD muscle biopsy transcriptomic samples. This suggests that 447 gene expression changes in patient lymphocytes may reflect changes in the pathologically 448 damaged muscle. Such a finding requires confirmation with paired blood samples and muscle 449 biopsies, beyond the scope of this proof-of-principle study. Moreover, many putative FSHD 450 therapeutics in development target DUX4 and target gene expression 49,51,55,56 . We have 451
shown that DUX4 and its target genes are robustly expressed in FSHD blood cells in a 452 manner correlated with pathological muscle changes, thus anti-DUX4 therapy may be easily 453 monitored for dose-titration by blood cell based DUX4 expression assessment. 454 455
To summarise, we demonstrate that FSHD blood borne lymphocytes continuously express 456 DUX4 and its target genes, in contrast to a burst like pattern seen in muscle cells. FSHD 457 lymphocyte gene expression also contributes to DUX4 target gene expression in FSHD 458 muscle biopsies, and associates with early stage microscopic histological inflammation. We 459
propose that FSHD immune cells may contribute to DUX4-mediated pathology in FSHD, and 460 that blood cell based transcriptomic biomarkers may prove useful minimally-invasive new 461 tools for the assessment of FSHD disease activity, progression and therapeutic monitoring. 462
Materials and Methods 463 464
Cell Culture of FSHD LCLs and primary myoblasts 465 Lymphoblastoid FSHD cell lines GSM16283, GSM16414, GSM16278 and respective control  466 lines GSM16281, GSM16320, GSM16412 were cultured in suspension in RPMI -1640 467 medium, supplemented with L-glutamine, sodium bicarbonate (Sigma), 10% FBS (Sigma) 468
and gentamycin (Gibco). Cell pellets were collected from three independent flasks for each 469 cell line. 470 471
Cell pellets corresponding to FSHD primary myoblast cell lines FSHD3 (FSHD1, 7RU, 472 female), FSHD6 (FSHD1, 8RU, female) and FSHD9 (FSHD1, 7RU, male) alongside age and 473 gender matched controls, in proliferation and after 3 days of differentiation into 474 multinucleated myotubes, in singlet, were kind gifts from Dr Dalila Laoudj-Chenivesse. 475 476
RNA-sequencing of FSHD LCLs and primary myoblasts 477
RNA was isolated using miRNeasy kit (Qiagen) including a DNAse digestion step. Prior to 478 sequencing RNA was analysed by LabChip Bioanalyzer, Qubit fluoremetric quantification 479
and Nanodrop quantification concentration and stability. RNA-seq libraries were prepared 480 using the sureselect stranded RNAseq protocol (Illumina), which allows polyA selection but 481 was modified to work with ribodepletion (Agilent). Libraries were sequenced on an Illumina 482
HiSeq2500. 483 484
Raw reads were trimmed using trim-galore, utilising cutadapt14 (v0.4.0) to remove the 485
Illumina Sequencing Adapter (AGATCGGAAGAGC) at the 3' end. Additionally, 12 bases 486 were also trimmed from the 5' end, in both myoblast and LCL samples and 5 bases from the 487 3' end in the LCL samples, since they showed a biased distribution. Reads were mapped to 488 the human transcriptome using the human genome sequence GRCh38 and v82 gene 489
annotations downloaded from Ensembl. Mapping was performed using tophat 15 (v2.1.0) and 490 bowtie 16 (v1.1.0), enabling the fr-firststrand option of tophat to restrict mapping to the sense 491 strand of the transcript. Reads were assigned to genes using the featureCounts program 17 492 (v1.5.0), counting fragments and ignoring multi-mapping reads, and restricted to the sense 493 strand. The resulting matrix of read counts was analysed using R. 494 495
Data describing the myoblast and LCLs were processed in separate batches and therefore 496 analysed as separate datasets. Both datasets were normalised using the DESeq2 package 57 in 497 R. 498 499
Public data on FSHD myoblasts, myotubes and muscle biopsies 500
Data containing myoblast and myotube RNA-seq samples in triplicate from immortalised 501 FSHD myoblast cell lines 54-2, 54-12, 54-A5, 16ABic and 16UBic and matched controls 54-502 A10, 54-6, 16UBic and 12UBic that we previously described 23 All data was log-transformed and quantile normalised within study for computation of the 523 DUX4, FSHD Lymphoblast and PAX7 scores, in line with our previously described 524 methodology 23 . 525 526
DUX4 detection, differential expression analysis and derivation of the FSHD Lymphoblast 527
Score 528
In all RNA-seq datasets, DUX4 detection was reported as positive if a single read was present 529
in the normalised data set. 530 531
Differential expression analysis of the LCL data was performed using the DESeq2 package in 532 R 57 to identify genes associated with FSHD independently of gender and matched-control 533 pair, feature significance was confirmed via p-value histogram. 534 535
The top 500 significant genes were considered for further analysis. The FSHD LCLs were 536 found to express high levels of DUX4 and DUX4 target genes, and DUX4 is a transcriptional 537 activator with repressed genes adding no power in previous FSHD biomarkers 23 . We thus 538 considered the mean expression of the 237/500 genes that were upregulated in FSHD LCLs 539 in a given sample, as a potential FSHD biomarker, referred to as the FSHD Lymphoblast 540 score. 541 542
Statistics 543
Biomarker computation and evaluation: Computation of the three DUX4 expression 544 biomarkers and PAX7 target gene repression biomarker were as previously described 23,24 . 545
Briefly, each DUX4 target gene expression score is computed for each sample as the mean 546 expression of the genes found to be up-regulated by the studies of Yao gene repression score for each sample was computed as the t-score from a test comparing the 549 up-regulated (311 genes) to down-regulated (290 genes) PAX7 target genes within each 550 sample. We have published a software for the computation of each of these scores from 551
suitably normalised dataset 24 . The FSHD Lymphoblast score was computed in each sample as 552 the mean expression of the 237 genes found up-regulated in FSHD LCLs. 553 554
For myoblast, myotube and LCL samples, the 3 DUX4 scores and the FSHD Lymphoblast 555 score were evaluated and z-normalised within matched control pairs. Score differences 556 between FSHD and controls samples were then evaluated within each cell type via a 557
Wilcoxon U-test. ROC curve analysis and AUC computation was performed using the pROC 558 package in R 58 . 559 560
For FSHD muscle biopsy samples the 3 DUX4 scores, the FSHD Lymphoblast score and the 561 PAX7 score were computed for each sample and z-normalised within each of the 7 studies. 562
Score differences between FSHD and control samples were evaluated within each study via 563
Wilcoxon U-test. In the case of the FSHD Lymphoblast score, meta-analysis across the 7 564 independent studies was performed using a random effects model, and overall significance 565 assessed via Fisher's combined test. ROC curve analysis, AUC computation and DeLong's 566 test were performed using all z-normalised scores for all studies combined, via the pROC 567 package in R 58 . 568 569
Correlation analyses: Pearson correlations between the 3 DUX4 scores and DUX4 expression 570
were computed using the base package in R separately across LCL, myoblast, myotube and 571 single cell myocyte samples following z-normalisation within control matched pairs. Pearson 572 correlations between the 3 DUX4 scores and the FSHD Lymphoblast score were computed 573 using the base package in R, following z-normalisation within each of the 7 studies 574 considered. 575 576
In the case of the muscle biopsy dataset described by Wang controls on meta-analysis of 7 independent data sets. 801 A forest plot displays the significance of the FSHD Lymphoblast score as a discriminator of 802 FSHD muscle biopsies in the 7 independent data sets assessed (A). Green boxes denote the 803 mean difference in FSHD Lymphoblast score between FSHD and control muscle biopsies 804
and whiskers denote the 95% confidence interval. A vertical line denotes a score difference 805 of 0 and datasets where the whiskers cross this line have not attained significance at the 5% 806 level (as assessed by Wilcoxon U-test). Numerical values for mean score difference and 807 confidence interval are displayed for each dataset on the left of the plot with significance 808 denoted by asterisks as follows: *: p<0.05, **: p<0.01, ***: p<0.001. The overall estimate is 809 displayed as a diamond and was computed using a random effects model with significance 810 assessed via Fisher's combined test. On meta-analysis the FSHD Lymphoblast score is 811 elevated on FSHD samples, and achieves strongest significance on the Wang et al., 2019 26 812 dataset, where muscles displaying evidence of active disease on MRI were preferentially 813 biopsied. A ROC curve displays the discriminatory capacity of the FSHD Lymphoblast score 814 on all muscle biopsy datasets combined (B). The FSHD Lymphoblast score was computed on 815 each muscle biopsy sample and z-normalised within each of the 7 independent studies before 816 being pooled for ROC curve analysis. The AUC of the FSHD Lymphoblast score as a 817 discriminator of FSHD muscle biopsies is displayed alongside the Wilcoxon p-value 818 comparing normalised FSHD Lymphoblast score values in FSHD muscle biopsies to controls 819 820 Tables summarise multivariate regression analyses on the dataset described by Wang 
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Figure S3: The FSHD Lymphoblast score represents a moderately powered biomarker for FSHD muscle biopsies, equivalent to DUX4 target gene expression but inferior to PAX7 target gene repression.
A ROC curve displays the discriminatory capacity of the FSHD Lymphoblast score (blue), the Choi et al., 2016 38 early (8 hour) DUX4 target gene signature (green), the Yao et al., 2014 21 later (24-48 hour) DUX4 target gene signature (red), the Geng et al., 2012 20 later (24 hour) DUX4 target gene signature (pink) and the PAX7 target gene repression score (brown) on all muscle biopsy datasets combined. Each score was computed on each muscle biopsy sample and z-normalised within each of the 7 independent studies before being pooled for ROC curve analysis. The AUC for each score is displayed alongside DeLong's test p-value comparing the discriminatory power of the biomarkers. FSHD Lymphoblast score displays a discriminatory power similar to DUX4 target gene signatures, but inferior to PAX7 target gene repression. 
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